Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 211 - 234 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |